Pederin and Psymberin Related Agents for Biomolecule Conjugation

This technology features a series of potent cytotoxic compounds derived from natural product scaffolds such as pederin, psymberin, and mycalamide. It incorporates a functionalized tetrahydropyran subunit and an N-acyl aminal linkage that work together to inhibit protein synthesis by binding to the 60S ribosomal subunit and displacing tedanolide. The detailed synthetic routes include steps like asymmetric allylation, stereoselective aldol reactions, and cycloadditions that enable the construction of their complex molecular architectures. Specific modification sites allow for the attachment of linkers to conjugate these compounds with antibodies, dendrimers, or liposomes for targeted delivery.

Description

What differentiates this approach is its precision in structural modification at key positions, such as C10 and C13 in the pederin framework and C8 and C11 in psymberin. These modifications create a platform that not only maintains high potency but also addresses general toxicity by optimizing selective drug delivery. The innovative synthetic strategy and adaptable linker conjugation enable exploration of structure-activity relationships, thereby enhancing therapeutic efficacy while mitigating off-target effects, offering a promising advancement in targeted cancer treatment.

Applications

- Targeted cancer therapeutics
- Antibody-drug conjugate development
- Precision oncology formulations
- Synthetic anticancer agent production

Advantages

- Potent anticancer activity through targeted inhibition of protein synthesis and induction of apoptosis.
- Enables selective delivery by conjugating to antibodies, dendrimers, or liposomes via functional linker modifications.
- Comprehensive synthetic methodologies facilitate the generation of diverse analogs for structure-activity optimization.
- Strategic functional modifications help reduce general toxicity, potentially improving the therapeutic window.
- Versatile design allows fine-tuning of therapeutic properties through controlled modifications at key positions.

IP Status

https://patents.google.com/patent/US9364555B2

Quick Facts:
Reference Number
02520
Technology Type
Therapeutic Modality
Technology Subtype
Drug Delivery / Formulation
Therapeutic Areas
Oncology
Lead Inventor
Paul Floreancig
Department
Chemistry
All Tech Innovators
Billy W. DayPaul Edward FloreancigShuangyi WanFanghui Wu
Technology Readiness Level
2. Initial proof of concept, in-vitro
Date Submitted
2011-07-11